menu
    • menu
    [{"orgOrder":0,"company":"Guardant Health","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved","graph3":"Guardant Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Guardant Health \/ Blueprint Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Guardant Health \/ Blueprint Medicines"},{"orgOrder":0,"company":"Guardant Health","sponsor":"AnHeart Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Guardant Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Guardant Health \/ AnHeart Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Guardant Health \/ AnHeart Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Guardant Health

    Menu

    Guardant Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Guardant Health

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Guardant Health

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taletrectinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : AnHeart Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 T...

                            Details : Under the terms of the collaboration, Guardant Health and AnHeart Therapeutics will develop Guardant360® CDx and Guardant360 TissueNext™ assays as companion diagnostics for AB-106 (taletrectinib) in Advanced or Metastatic ROS1-Positive NSCLC.

                            Product Name : AB-106

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 02, 2023

                            Lead Product(s) : Taletrectinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : AnHeart Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Guardant Health

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Guardant Health

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Osimertinib Mesylate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Blueprint Medicines

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Guardant Health and Blueprint Medicines Present Real-world Data Identifying EGFR C797x Mutation as Most Common...

                            Details : Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line Tagrisso (osimertinib) treatment.

                            Product Name : Tagrisso

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 08, 2022

                            Lead Product(s) : Osimertinib Mesylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Blueprint Medicines

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth